Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 3/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.39 |
| ▸ | RARA | P10276 | 1/20 | 0.39 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
| ▸ | RARG | P13631 | 1/20 | 0.39 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12365277 | 0.93 | PDK2 (0.42) | PDK2MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL12365830 | 0.88 | PDK2 (0.40) | PDK2MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL12365069 | 0.88 | PDK2 (0.43) | PDK2MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL6068739 | 0.88 | L3MBTL1 (0.42) | PDK2KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL12389147 | 0.86 | TDP1 (0.42) | MAPK14KDM4EALDH1A1HPGDL3MBTL1 | |
| SCHEMBL12364995 | 0.86 | PDK2 (0.45) | PDK2MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL12365333 | 0.86 | TDP1 (0.42) | PDK2MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL12389756 | 0.86 | MAPT (0.45) | PDK2MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL12365000 | 0.86 | MAPK14 (0.43) | PDK2MAPK14KDM4EALDH1A1HPGD | |
| SCHEMBL12364992 | 0.86 | SRD5A2 (0.49) | PDK2KDM4EALDH1A1L3MBTL1RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | PDK2 3920/4885MAPK14 3304/4885KDM4E 1455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.